false
0001699709
0001699709
2026-01-27
2026-01-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
January 27, 2026
VitaNova
Life Sciences Corporation
(Exact Name of Registrant as Specified in its
Charter)
| Nevada
|
|
333-218733
|
|
35-2583762 |
| (State
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
39
E Broadway, Suite 603, New York,
NY 10002
(Address of principal office)
+1-516-886-8888
(Registrant’s telephone number, including
area code)
Yijia Group Corp.
(Former Name or former address if changed from
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock |
|
YJGJD |
|
OTC Pink Sheets |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
As previously reported on the Current Reports
on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 7, 2025 and January 13, 2026,
respectively, Yijia Group Corp. (the “Company”) proposed to change the name of the Company to VitaNova Life Sciences
Corporation (the “Name Change”), and the Name Change was effectuated on January 9, 2026, through a Certificate of Amendment
to the Articles of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of
Nevada. As of the date of this Current Report on Form 8-K (this “Report”), the Financial Industry Regulatory Authority
(“FINRA”) has completed its review of the Name Change and has announced that the Name Change will be reflected for
purposes of trading on the OTC Pink marketplace as of January 27, 2026.
As previously reported, the Company also proposed
to effect a reverse stock split at a ratio within the range from 1-for-2 to 1-for-3, which was approved by the Company’s Board of
Directors (the “Board”) and a majority of the holders of the Company’s issued and outstanding shares of common
stock. The Board further approved the reverse stock split to be effectuated at the ratio of 1-for-3, such that each holder of common stock
of the Company will receive one (1) share of common stock for every three (3) shares of common stock held (the “Reverse Split”).
The Certificate of Amendment also effectuated the Reverse Split on January 9, 2026. As of the date of this Report, FINRA has completed
its review of the Reverse Split and has announced that the Reverse Split will be given effect for the purposes of trading on the OTC Pink
marketplace as of January 27, 2026.
In connection with the Name Change, the Company
has requested that FINRA change the ticker symbol of its common stock to “VNOV” (the “New Ticker”). The
Company’s common stock will continue to trade under the symbol of “YJGJ,” with the letter “D” added to the
end of the trading symbol for a period of 20 trading days beginning on January 27, 2026, after which the Company’s trading symbol
will be changed to the New Ticker. The Company has also obtained a new CUSIP number for its common stock in connection with the Name Change
and the Reverse Split, which is 98585W403.
No action is required by current stockholders
in relation to the announcement of the Name Change, Reverse Split, and New Ticker.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
| Exhibit |
|
Description |
| |
|
|
| 3.1 |
|
Certificate of Amendment, dated January 9, 2026* |
| 104 |
|
Cover Page Interactive File (embedded within the Inline XBRL document) |
*Previously filed as exhibits to the Company’s
Current Report as filed with the SEC on January 13, 2026.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: January 27, 2026
| VitaNova
Life Sciences Corporation |
|
| |
| |
|
|
| By: |
/s/
Qiuping Lu |
|
|
Qiuping Lu |
|
| |
Chief Executive Officer and Director
(Principal Executive Officer) |
|
